Entia at-home full blood count analyser to be deployed at NHS trusts
An innovative at-home monitoring solution for cancer patients, the Liberty full blood count analyser developed by Entia, has received approval for use in the UK. Scheduled to launch in two NHS trusts in 2024, this device aims to detect life-threatening complications in cancer patients.
Following the UK Conformity Assessed (UKCA) mark received in November 2023, the Liberty analyser will be rolled out at Shrewsbury and Telford NHS Hospital Trust and the Christie NHS Foundation Trust by September 2024. Entia plans to expand the deployment to an additional 12 hospitals across the UK by the end of the same year.
The solution has already undergone successful testing with over 1,000 cancer patients from various treatment centers in the UK, including the Christie. This innovative approach to monitoring aims to provide patients with a more convenient and reliable way to manage their health.
Dr Toby Basey-Fisher, founder and CEO of Entia, expressed optimism about the impact of the Liberty analyser, stating, “Receiving the UKCA mark has given us the opportunity to enhance patient care and accelerate the adoption of patient-centric oncology practices in the UK.”
By offering a comprehensive blood analysis from a simple home finger prick test, Entia’s Liberty device eliminates the need for frequent outpatient appointments, saving patients time and resources. This not only enhances patient convenience but also empowers healthcare providers with real-time data to ensure timely interventions.
Furthermore, Dr. Sacha Howell from the Christie NHS Foundation Trust highlighted the potential of the Liberty analyser to improve patient experience, stating, “By reducing the number of clinic visits, this device could significantly improve patients’ quality of life during cancer treatment.”
Dr. Laura Pettit from Shrewsbury and Telford NHS Hospital Trust emphasized the convenience of at-home monitoring, noting, “Enabling patients to perform blood tests from home could offer more flexibility and reduce unnecessary hospital visits.”
Entia envisions that the implementation of at-home monitoring could lead to the development of AI-based predictive tools to further enhance clinical decision-making. With the UKCA mark highlighting compliance with UK regulations, the deployment of the Liberty analyser marks a significant advancement in cancer patient care.
